Palliation. Treating patients with inoperable biliary tract and primary liver tumors

Surgical Oncology Clinics of North America

Volumn 23, Issue 2, 2014, Pages 383-397

  Amini, Albert ^a   Gamblin, T Clark ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Chemoembolization; Cholangiocarcinoma; Endoscopic therapies; Hepatocellular carcinoma; Palliation; Systemic therapies; Targeted therapies

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ERLOTINIB; FLOXURIDINE; FLUOROURACIL; GELFOAM; GEMCITABINE; IODINATED POPPYSEED OIL; IODINE 131; IRINOTECAN; MICROSPHERE; MITOMYCIN; OXALIPLATIN; PLACEBO; SORAFENIB; YTTRIUM 90;

ADVANCED CANCER; BILE DUCT CARCINOMA; BILIARY STENT; BILIARY TRACT CANCER; BILIARY TRACT DRAINAGE; BILIARY TRACT TUMOR; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CRYOABLATION; DRUG INFUSION; ENDOSCOPIC THERAPY; EXTERNAL BEAM RADIOTHERAPY; HEPATIC ARTERY; HEPATIC ARTERY INFUSION; HUMAN; LIPID ABSORPTION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; LOW DRUG DOSE; MICROWAVE THERAPY; NUTRITIONAL STATUS; OBSTRUCTIVE JAUNDICE; OVERALL SURVIVAL; PERCUTANEOUS ETHANOL INJECTION; PROGRESSION FREE SURVIVAL; PRURITUS; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; TUMOR ABLATION; TUMOR NECROSIS;

CHEMOEMBOLIZATION; CHOLANGIOCARCINOMA; ENDOSCOPIC THERAPIES; HEPATOCELLULAR CARCINOMA; PALLIATION; SYSTEMIC THERAPIES; TARGETED THERAPIES;

BILIARY TRACT NEOPLASMS; HUMANS; LIVER NEOPLASMS; PALLIATIVE CARE;

EID: 84896725718     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.10.008     Document Type: Review

References (103)

1. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. NEngl J Med 1999, 340:745-750.
2. Patel T. Increasing incidence of mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33:1353-1357.
3. Endo I., Gonen M., Yopp A.C., et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcomes after resection. Ann Surg 2008, 248(1):1-13.
4. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. JClin Oncol 2009, 27:1485-1491.
5. Cunningham S.C., Choti M.A., Bellavance E.C., et al. Palliation of hepatic tumors. Surg Oncol 2007, 16:277-291.
6. Bruix J., Boix L., Sala M., et al. Focus on hepatocellular carcinoma. Cancer Cell 2004, 5:215-219.
7. Fattovich G., Stroffolini T., Zagni I., et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
8. Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001, 48:251-259.
9. Fuss M., Thomas C.R. Stereotactic body radiation therapy: an ablative treatment option for primary and secondary liver tumors. Ann Surg Oncol 2004, 11:130-138.
10. Khan S.A., Davidson B.R., Goldin R.D., et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012, 61:1657-1669.
11. Khan S.A., Thomas H.C., Davidson B.R., et al. Cholangiocarcinoma. Lancet 2005, 366:1303-1314.
12. Jarnagin W.R. Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol 2000, 19:156-176.
13. Llovet J.M., Schwartz M., Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25:181-200.
14. Forner A., Reig M.E., de Lope C.R., et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010, 30:61-74.
15. Fan S.T., Lo C.M., Liu C.L., et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999, 229:322-330.
16. Colella G., Bottelli R., De Carlis L., et al. Hepatocellular carcinoma: comparison between liver transplantation, respective surgery, ethanol injection and chemoembolization. Transpl Int 1998, 11(1):S193-S196.
17. Fong Y., Sun R.L., Jarnagin W., et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999, 229:1669-1677.
18. Groeschl R.T., Gamblin T.C., Turaga K.K. Ablation for hepatocellular carcinoma: validating the 3-cm breakpoint. Ann Surg Oncol 2013, 20:3591-3595. 10.1245/s10434-013-3031-5.
19. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255.
20. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
21. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of Sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
22. Nguyen K.T., Steel J., Vanounou T., et al. Initial presentation and management of hilar and peripheral cholangiocarcinoma: is a node-positive status or potential margin-positive result a contraindication to resection?. Ann Surg Oncol 2009, 16:3308-3315.
23. Gusani N.J., Balaa F.K., Steel J.L., et al. Treatment of unresectable cholangiocarcinoma with Gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. JGastrointest Surg 2008, 12:129-137.
24. Tan J.C., Coburn N.G., Baxter N.N., et al. Surgical management of intrahepatic cholangiocarcinoma-a population-based study. Ann Surg Oncol 2008, 15:600-608.
25. Chahal P., Baron T.H. Endoscopic palliation of cholangiocarcinoma. Curr Opin Gastroenterol 2006, 22:551-560.
26. Goletti O., Lencioni R., Armillotta N., et al. Laparoscopic radiofrequency thermal ablation of hepatocarcinoma: preliminary experience. Surg Laparosc Endosc Percutan Tech 2000, 1:284-290.
27. Montorsi M., Santambrogio R., Bianchi P., et al. Radiofrequency interstitial thermal ablation of hepatocellular carcinoma in liver cirrhosis. Role of the laparoscopic approach. Surg Endosc 2001, 15:141-145.
28. Livraghi T., Goldberg S.N., Lazzaroni S., et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000, 214:761-768.
29. Livraghi T., Meloni F., Di Stasi M., et al. Sustained complete response and complication rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 2008, 47:82-89.
30. Sala M., Llovet J.M., Vilana R., et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004, 40:1352-1360.
31. Poon R.T., Fan S.T., Tsang F.H., et al. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002, 235(4):466-486.
32. Kim J.H., Won H.J., Shim Y.M., et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 2011, 196:W205-W209.
33. Kuhlman J.B., Blum H.E. Locoregional therapy for cholangiocarcinoma. Curr Opin Gastroenterol 2013, 29:1-5.
34. Shina S., Tagawa K., Unuma T., et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. Cancer 1991, 68:1524-1530.
35. Livraghi T., Giorgio A., Marin G., et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995, 197:101-108.
36. Vilana R., Bruix J., Bru C., et al. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992, 16:353-357.
37. Gournay J., Tchuenbou J., Richou C., et al. Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case-control study with cost analysis. Aliment Pharmacol Ther 2002, 16:1529-1538.
38. Livraghi T., Goldberg S.N., Lazzaroni S., et al. Small hepatocellular carcinoma; treatment with radiofrequency ablation versus percutaneous ethanol injection. Radiology 1999, 210:655-661.
39. Ravikumar T.S., Steele G.D. Hepatic cryosurgery. Surg Clin North Am 1989, 69:433-440.
40. Cuschieri A., Crosthwaite G., Shimi S., et al. Hepatic cryotherapy for liver tumors. Development and clinical evaluation of a high-efficiency insulated multineedle probe system for open and laparoscopic use. Surg Endosc 1995, 9:483-489.
41. Zhou X.D., Tang Z.Y. Management of hepatocellular carcinoma: long-term outcome in 2639 cases. Gan To Kagaku Ryoho 1997, 24:9-16.
42. Huang Y.Z., Zhou S.C., Zhou H., et al. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013, 60. 10.5754/hge121142.
43. Seki T., Wakabayashi M., Nakagawa T., et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994, 74:817-825.
44. Matsukawa T., Yamashita Y., Arakawa A., et al. Percutaneous microwave coagulation therapy in liver tumors. A 3-year experience. Acta Radiol 1997, 38:410-415.
45. Ohmoto K., Miyake I., Tsuduki M., et al. Percutaneous microwave coagulation therapy for unresectable hepatocellular carcinoma. Hepatogastroenterology 1999, 46:2894-2900.
46. Groeschl R.T., Wong R.K., Quebbeman E.J., et al. Recurrence after microwave ablation of liver malignancies: a single institution experience. HPB (Oxford) 2013, 15:365-371.
47. Chung K.Y., Kemeny N. Regional and systemic chemotherapy for primary hepatobiliary cancers and for colorectal cancer metastatic to the liver. Semin Radiat Oncol 2005, 15:284-298.
48. Tse A.N., Wu N., Patel D., et al. Aphase 1 study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemother Pharmacol 2009, 64:935-944.
49. Jarnagin W., Schwartz L., Gultekin D.H., et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009, 20:1589-1595.
50. Bhattacharya S., Davidson B., Dhillon A.P. Blood supply of early hepatocellular carcinoma. Semin Liver Dis 1995, 15:390-401.
51. Bruix J., Castells A., Montanya X., et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology 1994, 20:643-650.
52. Matsui O., Kadoya M., Yoshikawa J., et al. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 1994, 33:S84-S88.
53. Bhattacharya S., Novell J.R., Winslet M.C., et al. Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 1994, 81:1563-1571.
54. Hatanaka Y., Yamashita Y., Takahashi M., et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 1995, 195:747-752.
55. Ma T.C., Shao H.B., Xu Y., et al. Three treatment methods via the hepatic artery for hepatocellular carcinoma-a retrospective study. Asian Pac J Cancer Prev 2013, 14:2491-2494.
56. Sumie S., Yamashita F., Ando E., et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol 2003, 181:1327-1334.
57. Okusaka T., Kasugai H., Shioyama Y., et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. JHepatol 2009, 51:1030-1036.
58. Llovet J.M., Real M.I., Montana X., et al. Arterial embolization or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 18:1734-1739.
59. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
60. Park S.Y., Kim J.H., Yoon H.J., et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 2011, 66:322-328.
61. Kuhlmann J.B., Euringer W., Spangenberg H.C., et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 2012, 24:437-443.
62. Raoul J.I., Bretagne J.F., Caucanas J.P., et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine-131-labeled Lipiodol. Cancer 1992, 9:346-352.
63. Leung W.T., Lau W.Y., Ho S., et al. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. JNucl Med 1994, 35:1313-1318.
64. Yoo H.S., Park C.H., Lee J.T., et al. Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol. Cancer Chemother Pharmacol 1994, 33:S128-S133.
65. Raoul J.L., Guyader D., Bretagne J.F., et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131-1-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997, 26:1156-1161.
66. Lau W.Y., Leung W.T., Ho S., et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994, 70:994-999.
67. Hoffman R.T., Paprottka P.M., Schon A., et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012, 35:106-116.
68. Saxena A., Bester L., Chua T.C., et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010, 17:484-491.
69. Minami Y., Kudo M. Radiofrequency ablation of hepatocellular carcinoma: a literature review. Int J Hepatol 2011, 2011:104685.
70. Kuang M., Xie X.Y., Huang C., et al. Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. JGastrointest Surg 2011, 15:2165-2171.
71. Oliveri R.S., Wetterslev J., Gluud C. Transarterial (chemo) embolization for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011, (3). CD004787.
72. Young R.F. The role of the gamma knife in the treatment of malignant primary and metastatic brain tumors. CA Cancer J Clin 1998, 48:177-188.
73. Lo S.S., Dawson L.A., Kim E.Y., et al. Stereotactic body radiation therapy for hepatocellular carcinoma. Discov Med 2010, 9:404-410.
74. Ibarra R.A., Rojas D., Snyder L., et al. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. Acta Oncol 2012, 51:575-583.
75. Kwon J.H., Bae S.H., Kim J.Y., et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic Radiotherapy Liver Cancer. BMC Cancer 2010, 10:475.
76. Barney B.M., Olivier K.R., Miller R.C., et al. Clinical outcomes and toxicity using stereotactic body radiotherapy for advanced cholangiocarcinoma. Radiat Oncol 2012, 7:1-7.
77. Blechacz B., Gores G.J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008, 48:308-321.
78. Smith A.C., Dowsett J.F., Russell R.C., et al. Randomized trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet 1994, 344:1655-1660.
79. Dowsett J.F., Vaira D., Hatfield A.R., et al. Endoscopic biliary therapy using the combined percutaneous and endoscopic technique. Gastroenterology 1989, 96:1180-1186.
80. Hintze R.E., Abou-Rebyeh H., Adler A., et al. Magnetic resonance cholangiopancreatography guided unilateral endoscopic stent placement for Klatskin tumors. Gastrointest Endosc 2001, 53:40-46.
81. Freeman M.L., Overby C. Selective MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents. Gastrointest Endosc 2003, 58:41-49.
82. De Palma G.D., Galloro G., Siciliano S., et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001, 53:547-553.
83. Raju R.P., Jaganmohan S.R., Ross W.A., et al. Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci 2011, 56:1557-1564.
84. Shariff M.I., Khan S.A., Westaby D. The palliation of cholangiocarcinoma. Curr Opin Support Palliat Care 2013, 7:1-7.
85. Ortner M.A., Dorta G. Technology insight: photodynamic therapy for cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006, 3:459-467.
86. Ortner M.E., Caca K., Berr F., et al. Successful photodynamic therapy for non-resectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003, 125:1355-1363.
87. Witzigmann H., Berr F., Ringel U., et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006, 244:230-239.
88. Gerhards M.F., van Gulik T.M., Gonzalez Gonzalez D., et al. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003, 27:173-179.
89. Montemaggi P., Costamagna G., Dobelbower R.R., et al. Intraluminal brachytherapy in the treatment of pancreas and bile duct carcinoma. Int J Radiat Oncol Biol Phys 1995, 32:437-443.
90. Choi J., Ryu J.K., Lee S.H., et al. Biliary drainage for obstructive jaundice caused by unresectable hepatocellular carcinoma: the endoscopic versus percutaneous approach. Hepatobiliary Pancreat Dis Int 2012, 11:636-642.
91. Bahng S., Yoo B.C., Paik S.W., et al. Photodynamic therapy for bile duct invasion of hepatocellular carcinoma. Photochem Photobiol Sci 2013, 12:439-445.
92. Cho H.C., Lee J.K., Lee K.H., et al. Are endoscopic or percutaneous biliary drainage effective for obstructive jaundice caused by hepatocellular carcinoma?. Eur J Gastroenterol Hepatol 2011, 23:224-231.
93. Minami Y., Kudo M. Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage. Dig Dis 2012, 30:592-597.
94. Valle J.W., Wasan H., Johnson P., et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumors: a multicenter randomized phase II study-the UK ABD-01 study. Br J Cancer 2009, 101:621-627.
95. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. NEngl J Med 2010, 362:1273-1281.
96. Andre T., Tournigand C., Rosmorduc O., et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004, 15:1339-1343.
97. Harder J., Riecken B., Kummer O., et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006, 95:848-852.
98. Jang J.S., Lim H.Y., Hwang I.G., et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean cancer study group phase II trial. Cancer Chemother Pharmacol 2010, 65:641-647.
99. Eckel F., Schimd R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinic trials. Br J Cancer 2007, 96:896-902.
100. Lee J., Park S.H., Chang H., et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicenter, open-label, randomized, phase 3 study. Lancet Oncol 2012, 13:181-188.
101. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 359:378-390.
102. Galle P., Blanc J., Van Laethem J.L., et al. Efficacy and safety of Sorafenib in patients with advanced hepatocellular carcinoma and prior anti-tumor therapy: a subanalysis from the SHARP trial. JHepatol 2008, 48:s372.
103. Kudo M., Ueshima K. Positioning of a molecular-targeted agent, Sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 2010, 78:S154-S166.